Prognostic value of microRNAs in colorectal cancer: a meta-analysis
Received 19 November 2017
Accepted for publication 12 February 2018
Published 30 April 2018 Volume 2018:10 Pages 907—929
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Kenan Onel
Song Gao,1,* Zhi-Ying Zhao,2,* Rong Wu,1 Yue Zhang,3 Zhen-Yong Zhang1
1Second Department of Clinical Oncology, Shengjing Hospital of China Medical University, 2School of Computer Science and Engineering, Northeastern University, Shenyang, 3First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China
*These authors contributed equally to this work
Background: Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.
Materials and methods: Studies published in English that estimated the expression levels of miRNAs with survival curves in CRC were identified until May 20, 2017 by online searches in PubMed, Embase, Web of Science, and the Cochrane Library by two independent authors. Pooled HRs with 95% CIs were used to estimate the correlation between miRNA expression and overall survival.
Results: A total of 63 relevant articles regarding 13 different miRNAs, with 10,254 patients were ultimately included. CRC patients with high expression of blood miR141 (HR 2.52, 95% CI 1.68–3.77), tissue miR21 (HR 1.31, 95% CI 1.12–1.53), miR181a (HR 1.52, 95% CI 1.26–1.83), or miR224 (HR 2.12, 95% CI 1.04–4.34), or low expression of tissue miR126 (HR 1.55, 95% CI 1.24–1.93) had significantly poor overall survival (P<0.05).
Conclusion: In general, blood miR141 and tissue miR21, miR181a, miR224, and miR126 had significant prognostic value. Among these, blood miR141 and tissue miR224 were strong biomarkers of prognosis for CRC.
Keywords: microRNA, colorectal cancer, prognosis, meta-analysis
A Letter to the Editor has been received and published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]